Literature DB >> 21645271

Calculation of numbers-needed-to-treat in parallel group trials assessing ordinal outcomes: case examples from acute stroke and stroke prevention.

Philip Bath, Cheryl Hogg, Michael Tracy, Stuart Pocock.   

Abstract

BACKGROUND: Number-needed-to-treat describes the magnitude of the effect of an intervention, underpins health economic analyses, and is typically calculated for binary events. Ordered categorical outcomes provide more clinical information and their analysis using ordinal approaches is usually more efficient statistically. However, to date, techniques to calculate number-needed-to-treat based on ordinal outcomes for parallel group trials have had important limitations. Aims Numbers-needed-to-treat may be calculated for ordinal data from parallel group trials by using an unmatched comparison of all subjects or by generating matched pairs of patients nested within the study.
METHODS: The above approaches were assessed and compared with numbers-needed-to-treat calculated for binary outcomes using individual patient data from acute and prevention stroke trials testing the effect of interventions of varying utility and efficacy.
RESULTS: Numbers-needed-to-treat were generally lower numerically for ordinal vs. binary, and matched vs. unmatched analyses, and the lowest in highly efficacious interventions: hemicraniectomy, ordinal matched 2.4 vs. ordinal unmatched 2.5 vs. binary matched 12 vs. binary unmatched 9 (one trial, 12 month outcome); alteplase, 4.5 vs. 6.6 vs. 8.4 vs. 8.4 (one trial with two parts, three-months); aspirin, 42 vs. 58 vs. 76 vs. 80 (one trial, six-months); and stroke units, 3.6-5.3 vs. 6.2 vs. 4.7-5.9 vs. 6.3-7.0 (two trials, three- to 60 months). Similar trends were seen for aspirin/dipyridamole vs. aspirin in secondary prevention, 22 vs. 20 vs. 31 vs. 31 (one trial, 24 months).
CONCLUSIONS: Number-needed-to-treat may be calculated for ordinal outcome data derived from parallel group stroke trials; such numbers-needed-to-treat are lower than those calculated for binary outcomes. Their use complements the use of ordinal statistical approaches in the analysis of ordered categorical data.
© 2011 The Authors. International Journal of Stroke © 2011 World Stroke Organization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21645271     DOI: 10.1111/j.1747-4949.2011.00614.x

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  6 in total

1.  Number needed to treat: A primer for neurointerventionalists.

Authors:  Juan Carlos Martinez-Gutierrez; Thabele Leslie-Mazwi; Ronil V Chandra; Kevin L Ong; Raul G Nogueira; Mayank Goyal; Felipe C Albuquerque; Joshua A Hirsch
Journal:  Interv Neuroradiol       Date:  2019-06-27       Impact factor: 1.610

2.  Association of an Early Intervention Service for Psychosis With Suicide Rate Among Patients With First-Episode Schizophrenia-Spectrum Disorders.

Authors:  Sherry Kit Wa Chan; Stephanie Wing Yan Chan; Herbert H Pang; Kang K Yan; Christy Lai Ming Hui; Wing Chung Chang; Edwin Ho Ming Lee; Eric Yu Hai Chen
Journal:  JAMA Psychiatry       Date:  2018-05-01       Impact factor: 21.596

3.  Analysis of the Modified Rankin Scale in Randomised Controlled Trials of Acute Ischaemic Stroke: A Systematic Review.

Authors:  Aimie Nunn; Philip M Bath; Laura J Gray
Journal:  Stroke Res Treat       Date:  2016-03-20

4.  The Missing Medians: Exclusion of Ordinal Data from Meta-Analyses.

Authors:  Toby B Cumming; Leonid Churilov; Emily S Sena
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

5.  Data sharing: experience of accessing individual patient data from completed randomised controlled trials in vascular and cognitive medicine.

Authors:  Polly Scutt; Lisa J Woodhouse; Alan A Montgomery; Philip M Bath
Journal:  BMJ Open       Date:  2020-09-09       Impact factor: 2.692

6.  Effect of continuing versus stopping pre-stroke antihypertensive agents within 12 h on outcome after stroke: A subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial.

Authors:  Lisa J Woodhouse; Jason P Appleton; Polly Scutt; Lisa Everton; Gwenllian Wilkinson; Valeria Caso; Anna Czlonkowska; John Gommans; Kailash Krishnan; Ann C Laska; George Ntaios; Serefnur Ozturk; Stephen Phillips; Stuart Pocock; Kameshwar Prasad; Szabolcs Szatmari; Joanna M Wardlaw; Nikola Sprigg; Philip M Bath
Journal:  EClinicalMedicine       Date:  2022-01-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.